APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuropeptide Y Receptor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuropeptide Y Receptor Market Outlook and Growth Opportunities 2026

5 July 2026190 pages

Choose your research edition.

Industry ResearchNeuropeptide Y Receptor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuropeptide Y Receptor Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neuropeptide Y Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuropeptide Y Receptor Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuropeptide Y Receptor Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Neuropeptide Y Receptor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuropeptide Y Receptor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuropeptide Y Receptor market include Gila Therapeutics, Novo Nordisk, XL-protein, Lilly Eli, Novartis, Pfizer, Merck & Co, Mannkind and Gilead Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuropeptide Y Receptor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuropeptide Y Receptor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuropeptide Y Receptor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuropeptide Y Receptor market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuropeptide Y Receptor Segment by Company

Gila Therapeutics

Novo Nordisk

XL-protein

Lilly Eli

Novartis

Pfizer

Merck & Co

Mannkind

Gilead Sciences

Genentech

Neuropeptide Y Receptor Segment by Type

Food Grade

Pharmaceutical Grade

Neuropeptide Y Receptor Segment by Application

Medicine

Food Additives

Others

Neuropeptide Y Receptor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuropeptide Y Receptor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuropeptide Y Receptor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuropeptide Y Receptor significant trends, drivers, influence factors in global and regions.

6. To analyze Neuropeptide Y Receptor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuropeptide Y Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuropeptide Y Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuropeptide Y Receptor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuropeptide Y Receptor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuropeptide Y Receptor industry.

Chapter 3: Detailed analysis of Neuropeptide Y Receptor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuropeptide Y Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuropeptide Y Receptor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuropeptide Y Receptor Industry Trends Table 2. Neuropeptide Y Receptor Industry Drivers Table 3. Neuropeptide Y Receptor Industry Opportunities and Challenges Table 4. Neuropeptide Y Receptor Industry Restraints Table 5. Global Neuropeptide Y Receptor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuropeptide Y Receptor Revenue Share by Company (2021-2026) Table 7. Global Neuropeptide Y Receptor Sales Volume by Company (t) & (2021-2026) Table 8. Global Neuropeptide Y Receptor Sales Volume Share by Company (2021-2026) Table 9. Global Neuropeptide Y Receptor Average Price (USD/t) of Company (2021-2026) Table 10. Global Neuropeptide Y Receptor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuropeptide Y Receptor Key Company Manufacturing Base & Headquarters Table 12. Global Neuropeptide Y Receptor Company, Product Type & Application Table 13. Global Neuropeptide Y Receptor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuropeptide Y Receptor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Food Grade Table 18. Significant Companies of Pharmaceutical Grade Table 19. Global Neuropeptide Y Receptor Sales Volume by Type 2021 VS 2025 VS 2032 (t) Table 20. Global Neuropeptide Y Receptor Sales Volume by Type (2021-2026) & (t) Table 21. Global Neuropeptide Y Receptor Sales Volume by Type (2027-2032) & (t) Table 22. Global Neuropeptide Y Receptor Sales Volume Share by Type (2021-2026) Table 23. Global Neuropeptide Y Receptor Sales Volume Share by Type (2027-2032) Table 24. Global Neuropeptide Y Receptor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Neuropeptide Y Receptor Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Neuropeptide Y Receptor Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Neuropeptide Y Receptor Sales Value Share by Type (2021-2026) Table 28. Global Neuropeptide Y Receptor Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Medicine Table 30. Significant Companies of Food Additives Table 31. Significant Companies of Others Table 32. Global Neuropeptide Y Receptor Sales Volume by Application 2021 VS 2025 VS 2032 (t) Table 33. Global Neuropeptide Y Receptor Sales Volume by Application (2021-2026) & (t) Table 34. Global Neuropeptide Y Receptor Sales Volume by Application (2027-2032) & (t) Table 35. Global Neuropeptide Y Receptor Sales Volume Share by Application (2021-2026) Table 36. Global Neuropeptide Y Receptor Sales Volume Share by Application (2027-2032) Table 37. Global Neuropeptide Y Receptor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Neuropeptide Y Receptor Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Neuropeptide Y Receptor Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Neuropeptide Y Receptor Sales Value Share by Application (2021-2026) Table 41. Global Neuropeptide Y Receptor Sales Value Share by Application (2027-2032) Table 42. Global Neuropeptide Y Receptor Sales by Region: 2021 VS 2025 VS 2032 (t) Table 43. Global Neuropeptide Y Receptor Sales by Region (2021-2026) & (t) Table 44. Global Neuropeptide Y Receptor Sales Market Share by Region (2021-2026) Table 45. Global Neuropeptide Y Receptor Sales by Region (2027-2032) & (t) Table 46. Global Neuropeptide Y Receptor Sales Market Share by Region (2027-2032) Table 47. Global Neuropeptide Y Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Neuropeptide Y Receptor Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Neuropeptide Y Receptor Sales Value Share by Region (2021-2026) Table 50. Global Neuropeptide Y Receptor Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Neuropeptide Y Receptor Sales Value Share by Region (2027-2032) Table 52. Global Neuropeptide Y Receptor Market Average Price (USD/t) by Region (2021-2026) Table 53. Global Neuropeptide Y Receptor Market Average Price (USD/t) by Region (2027-2032) Table 54. Global Neuropeptide Y Receptor Sales by Country: 2021 VS 2025 VS 2032 (t) Table 55. Global Neuropeptide Y Receptor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Neuropeptide Y Receptor Sales by Country (2021-2026) & (t) Table 57. Global Neuropeptide Y Receptor Sales Market Share by Country (2021-2026) Table 58. Global Neuropeptide Y Receptor Sales by Country (2027-2032) & (t) Table 59. Global Neuropeptide Y Receptor Sales Market Share by Country (2027-2032) Table 60. Global Neuropeptide Y Receptor Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Neuropeptide Y Receptor Sales Value Market Share by Country (2021-2026) Table 62. Global Neuropeptide Y Receptor Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Neuropeptide Y Receptor Sales Value Market Share by Country (2027-2032) Table 64. Gila Therapeutics Company Information Table 65. Gila Therapeutics Business Overview Table 66. Gila Therapeutics Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 67. Gila Therapeutics Neuropeptide Y Receptor Product Portfolio Table 68. Gila Therapeutics Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 72. Novo Nordisk Neuropeptide Y Receptor Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. XL-protein Company Information Table 75. XL-protein Business Overview Table 76. XL-protein Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 77. XL-protein Neuropeptide Y Receptor Product Portfolio Table 78. XL-protein Recent Development Table 79. Lilly Eli Company Information Table 80. Lilly Eli Business Overview Table 81. Lilly Eli Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 82. Lilly Eli Neuropeptide Y Receptor Product Portfolio Table 83. Lilly Eli Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 87. Novartis Neuropeptide Y Receptor Product Portfolio Table 88. Novartis Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 92. Pfizer Neuropeptide Y Receptor Product Portfolio Table 93. Pfizer Recent Development Table 94. Merck & Co Company Information Table 95. Merck & Co Business Overview Table 96. Merck & Co Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 97. Merck & Co Neuropeptide Y Receptor Product Portfolio Table 98. Merck & Co Recent Development Table 99. Mannkind Company Information Table 100. Mannkind Business Overview Table 101. Mannkind Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 102. Mannkind Neuropeptide Y Receptor Product Portfolio Table 103. Mannkind Recent Development Table 104. Gilead Sciences Company Information Table 105. Gilead Sciences Business Overview Table 106. Gilead Sciences Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 107. Gilead Sciences Neuropeptide Y Receptor Product Portfolio Table 108. Gilead Sciences Recent Development Table 109. Genentech Company Information Table 110. Genentech Business Overview Table 111. Genentech Neuropeptide Y Receptor Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 112. Genentech Neuropeptide Y Receptor Product Portfolio Table 113. Genentech Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Neuropeptide Y Receptor Distributors List Table 117. Neuropeptide Y Receptor Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Neuropeptide Y Receptor Product Image Figure 2. Global Neuropeptide Y Receptor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuropeptide Y Receptor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuropeptide Y Receptor Sales (2021-2032) & (t) Figure 5. Global Neuropeptide Y Receptor Sales Average Price (USD/t) & (2021-2032) Figure 6. Global Neuropeptide Y Receptor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Food Grade Image Figure 10. Pharmaceutical Grade Image Figure 11. Global Neuropeptide Y Receptor Sales Volume by Type (2021 VS 2025 VS 2032) & (t) Figure 12. Global Neuropeptide Y Receptor Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Neuropeptide Y Receptor Sales Volume Share by Type (2021-2032) Figure 14. Global Neuropeptide Y Receptor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Neuropeptide Y Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Neuropeptide Y Receptor Sales Value Share by Type (2021-2032) Figure 17. Medicine Image Figure 18. Food Additives Image Figure 19. Others Image Figure 20. Global Neuropeptide Y Receptor Sales Volume by Application (2021 VS 2025 VS 2032) & (t) Figure 21. Global Neuropeptide Y Receptor Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Neuropeptide Y Receptor Sales Volume Share by Application (2021-2032) Figure 23. Global Neuropeptide Y Receptor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Neuropeptide Y Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Neuropeptide Y Receptor Sales Value Share by Application (2021-2032) Figure 26. Global Neuropeptide Y Receptor Sales by Region: 2021 VS 2025 VS 2032 (t) Figure 27. Global Neuropeptide Y Receptor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Neuropeptide Y Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Neuropeptide Y Receptor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Neuropeptide Y Receptor Sales Value (2021-2032) & (US$ Million) Figure 31. North America Neuropeptide Y Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Neuropeptide Y Receptor Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Neuropeptide Y Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Neuropeptide Y Receptor Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Neuropeptide Y Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Neuropeptide Y Receptor Sales Value (2021-2032) & (US$ Million) Figure 37. South America Neuropeptide Y Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Neuropeptide Y Receptor Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Neuropeptide Y Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Neuropeptide Y Receptor Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Neuropeptide Y Receptor Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Food Grade
  • Pharmaceutical Grade
Applications
  • Medicine
  • Food Additives
  • Others
Companies covered
  • Gila Therapeutics
  • Novo Nordisk
  • XL-protein
  • Lilly Eli
  • Novartis
  • Pfizer
  • Merck & Co
  • Mannkind
  • Gilead Sciences
  • Genentech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuropeptide Y Receptor Sales Value (2021-2032)
  4. 1.2.2 Global Neuropeptide Y Receptor Sales Volume (2021-2032)
  5. 1.2.3 Global Neuropeptide Y Receptor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuropeptide Y Receptor Market Dynamics
  1. 2.1 Neuropeptide Y Receptor Industry Trends
  2. 2.2 Neuropeptide Y Receptor Industry Drivers
  3. 2.3 Neuropeptide Y Receptor Industry Opportunities and Challenges
  4. 2.4 Neuropeptide Y Receptor Industry Restraints
3 Neuropeptide Y Receptor Market by Company
  1. 3.1 Global Neuropeptide Y Receptor Company Revenue Ranking in 2025
  2. 3.2 Global Neuropeptide Y Receptor Revenue by Company (2021-2026)
  3. 3.3 Global Neuropeptide Y Receptor Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuropeptide Y Receptor Average Price by Company (2021-2026)
  5. 3.5 Global Neuropeptide Y Receptor Company Ranking (2024-2026)
  6. 3.6 Global Neuropeptide Y Receptor Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuropeptide Y Receptor Company Product Type and Application
  8. 3.8 Global Neuropeptide Y Receptor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuropeptide Y Receptor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuropeptide Y Receptor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuropeptide Y Receptor Market by Type
  1. 4.1 Neuropeptide Y Receptor Type Introduction
  2. 4.1.1 Food Grade
  3. 4.1.2 Pharmaceutical Grade
  4. 4.2 Global Neuropeptide Y Receptor Sales Volume by Type
  5. 4.2.1 Global Neuropeptide Y Receptor Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neuropeptide Y Receptor Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Neuropeptide Y Receptor Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Neuropeptide Y Receptor Sales Value by Type
  9. 4.3.1 Global Neuropeptide Y Receptor Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Neuropeptide Y Receptor Sales Value by Type (2021-2032)
  11. 4.3.3 Global Neuropeptide Y Receptor Sales Value Share by Type (2021-2032)
5 Neuropeptide Y Receptor Market by Application
  1. 5.1 Neuropeptide Y Receptor Application Introduction
  2. 5.1.1 Medicine
  3. 5.1.2 Food Additives
  4. 5.1.3 Others
  5. 5.2 Global Neuropeptide Y Receptor Sales Volume by Application
  6. 5.2.1 Global Neuropeptide Y Receptor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuropeptide Y Receptor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neuropeptide Y Receptor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neuropeptide Y Receptor Sales Value by Application
  10. 5.3.1 Global Neuropeptide Y Receptor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuropeptide Y Receptor Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neuropeptide Y Receptor Sales Value Share by Application (2021-2032)
6 Neuropeptide Y Receptor Regional Sales and Value Analysis
  1. 6.1 Global Neuropeptide Y Receptor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuropeptide Y Receptor Sales by Region (2021-2032)
  3. 6.2.1 Global Neuropeptide Y Receptor Sales by Region: 2021-2026
  4. 6.2.2 Global Neuropeptide Y Receptor Sales by Region (2027-2032)
  5. 6.3 Global Neuropeptide Y Receptor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuropeptide Y Receptor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuropeptide Y Receptor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuropeptide Y Receptor Sales Value by Region (2027-2032)
  9. 6.5 Global Neuropeptide Y Receptor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuropeptide Y Receptor Sales Value (2021-2032)
  12. 6.6.2 North America Neuropeptide Y Receptor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuropeptide Y Receptor Sales Value (2021-2032)
  15. 6.7.2 Europe Neuropeptide Y Receptor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuropeptide Y Receptor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuropeptide Y Receptor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuropeptide Y Receptor Sales Value (2021-2032)
  21. 6.9.2 South America Neuropeptide Y Receptor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuropeptide Y Receptor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuropeptide Y Receptor Sales Value Share by Country, 2025 VS 2032
7 Neuropeptide Y Receptor Country-level Sales and Value Analysis
  1. 7.1 Global Neuropeptide Y Receptor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuropeptide Y Receptor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuropeptide Y Receptor Sales by Country (2021-2032)
  4. 7.3.1 Global Neuropeptide Y Receptor Sales by Country (2021-2026)
  5. 7.3.2 Global Neuropeptide Y Receptor Sales by Country (2027-2032)
  6. 7.4 Global Neuropeptide Y Receptor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuropeptide Y Receptor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuropeptide Y Receptor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuropeptide Y Receptor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuropeptide Y Receptor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuropeptide Y Receptor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Gila Therapeutics
  2. 8.1.1 Gila Therapeutics Company Information
  3. 8.1.2 Gila Therapeutics Business Overview
  4. 8.1.3 Gila Therapeutics Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Gila Therapeutics Neuropeptide Y Receptor Product Portfolio
  6. 8.1.5 Gila Therapeutics Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Neuropeptide Y Receptor Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 XL-protein
  14. 8.3.1 XL-protein Company Information
  15. 8.3.2 XL-protein Business Overview
  16. 8.3.3 XL-protein Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 XL-protein Neuropeptide Y Receptor Product Portfolio
  18. 8.3.5 XL-protein Recent Developments
  19. 8.4 Lilly Eli
  20. 8.4.1 Lilly Eli Company Information
  21. 8.4.2 Lilly Eli Business Overview
  22. 8.4.3 Lilly Eli Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lilly Eli Neuropeptide Y Receptor Product Portfolio
  24. 8.4.5 Lilly Eli Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Neuropeptide Y Receptor Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Neuropeptide Y Receptor Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Merck & Co
  38. 8.7.1 Merck & Co Company Information
  39. 8.7.2 Merck & Co Business Overview
  40. 8.7.3 Merck & Co Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co Neuropeptide Y Receptor Product Portfolio
  42. 8.7.5 Merck & Co Recent Developments
  43. 8.8 Mannkind
  44. 8.8.1 Mannkind Company Information
  45. 8.8.2 Mannkind Business Overview
  46. 8.8.3 Mannkind Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mannkind Neuropeptide Y Receptor Product Portfolio
  48. 8.8.5 Mannkind Recent Developments
  49. 8.9 Gilead Sciences
  50. 8.9.1 Gilead Sciences Company Information
  51. 8.9.2 Gilead Sciences Business Overview
  52. 8.9.3 Gilead Sciences Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Gilead Sciences Neuropeptide Y Receptor Product Portfolio
  54. 8.9.5 Gilead Sciences Recent Developments
  55. 8.10 Genentech
  56. 8.10.1 Genentech Company Information
  57. 8.10.2 Genentech Business Overview
  58. 8.10.3 Genentech Neuropeptide Y Receptor Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Genentech Neuropeptide Y Receptor Product Portfolio
  60. 8.10.5 Genentech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuropeptide Y Receptor Value Chain Analysis
  2. 9.1.1 Neuropeptide Y Receptor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuropeptide Y Receptor Sales Mode & Process
  6. 9.2 Neuropeptide Y Receptor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuropeptide Y Receptor Distributors
  9. 9.2.3 Neuropeptide Y Receptor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst